A Case of Non-Resolving MEK Inhibitor-Associated Retinopathy
A Case of Non-Resolving MEK Inhibitor-Associated Retinopathy
复制标题
DOI：
10.1159/000503414
复制
发表时间：
2019-01-01
影响因子：
0.4
通讯作者：
Uwaydat, Sami H.
中科院分区：
文献类型：
--
作者：
Chancellor, John R.;Kilgore, David A.;Uwaydat, Sami H.
丝裂原活化激酶途径在细胞存活中起重要作用，并且其失调与诸如黑色素瘤的癌症相关。针对这一通路设计的药物与一种称为MEK受体相关性视网膜病变（MEKAR）的新实体中的浆液性视网膜脱离有关。MEKAR通常被描述为自限性，浆液性液体通常在不停用药物的情况下消退。我们提出了一个病例，其中患者接受治疗转移性黑色素瘤与lacnotuzumab，巨噬细胞集落刺激因子抑制剂，阻断有丝分裂原活化蛋白激酶通路的上游成分，发展浆液性视网膜病变，并没有解决，尽管停药。
The mitogen-activated kinase pathway plays an important role in cell survival, and its dysregulation is associated with cancers such as melanoma. Drugs designed to target this pathway have been associated with serous retinal detachments in a new entity termed MEK inhibitor-associated retinopathy (MEKAR). MEKAR has classically been described as self-limiting, with serous fluid often resolving without discontinuation of the drug. We present a case in which a patient undergoing treatment for metastatic melanoma with lacnotuzumab, a macrophage colony-stimulating factor inhibitor that blocks an upstream component of the mitogen-activated protein kinase pathway, developed serous retinopathy that did not resolve despite drug discontinuation.